Non-association of IL-16 rs4778889 T/C polymorphism with cancer risk in Asians: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 2, 2014, Pages 803-805

  Xu, Lin Lin ^a   Song, Zhi Chun ^b   Shang, Kun ^c   Zhao, Li Qin ^d   Zhu, Zhan Sheng ^e  

^a First People's Hospital of Yancheng City   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF SOUTH CHINA   (China)

^e XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; IL 16; Meta analysis; Polymorphism; rs4778889

Indexed keywords

INTERLEUKIN 16;

ARTICLE; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; META ANALYSIS; NEOPLASM; PATHOLOGY; PROGNOSIS; RISK FACTOR;

CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-16; NEOPLASMS; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS;

EID: 84894644019     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.2.803     Document Type: Article

References (15)

1. Azimzadeh P, Romani S, Mohebbi SR, et al (2011). Interleukin-16 (IL-16) gene polymorphisms in Iranian patients with colorectal cancer. J Gastrointestin Liver Dis, 20, 371-6.
2. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.
3. Center DM, Kornfeld H, Cruikshank WW (1996). Interleukin 16 and its function as a CD4 ligand. Immunol Today, 17, 476-81.
4. Chow MT, Moller A, Smyth MJ (2012). Inflammation and immune surveillance in cancer. Semin Cancer Biol, 22, 23-32.
5. Cruikshank WW, Center DM, Nisar N, et al (1994). Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression. Proc Natl Acad Sci USA, 91, 5109-13.
6. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
7. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
8. Gao LB, Liang WB, Xue H, et al (2009). Genetic polymorphism of interleukin-16 and risk of nasopharyngeal carcinoma. Clin Chim Acta, 409, 132-5.
9. Gao LB, Rao L, Wang YY, et al (2009). The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis, 30, 295-9.
10. Kim HS (1999). Assignment of human interleukin 16 (IL16) to chromosome 15q26.3 by radiation hybrid mapping. Cytogenet Cell Genet, 84, 93.
11. Kundu JK, Surh YJ (2012). Emerging avenues linking inflammation and cancer. Free Radic Biol Med, 52, 2013-37.
12. Li S, Deng Y, Chen ZP, et al (2011). Genetic polymorphism of interleukin-16 influences susceptibility to HBV-related hepatocellular carcinoma in a Chinese population. Infect Genet Evol, 11, 2083-8.
13. Mathy NL, Scheuer W, Lanzendörfer M, et al (2000). Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology, 100, 63-9.
14. Pharoah PD, Dunning AM, Ponder BA, Easton DF (2004). Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer, 4, 850-60.
15. Zhu J, Qin C, Yan F, et al (2010). IL-16 polymorphism and risk of renal cell carcinoma: association in a Chinese population. Int J Urol, 17, 700-7.